This study is testing if a combination of alpha-lipoic acid (ALA) and mirabegron can help your body process food better, especially if you have obesity and insulin resistance. Researchers want to see if this combination improves insulin sensitivity (how well your body uses insulin to control blood sugar). You might be eligible if you are between 18 and 65 years old and have a Body Mass Index (BMI) between 30 and 45 kg/m². The study aims to enroll 60 participants. The status of this study is currently unclear.

Study design

This is a Phase II, single-blinded (you won't know if you're getting the active treatment or placebo), randomized (assigned by chance), placebo-controlled crossover pilot study. It plans to enroll 48 participants.

What's involved

You will undergo screening, a physical exam, blood and urine tests, a heart function test, and speak with a dietician. You will take either mirabegron with alpha-lipoic acid or mirabegron with a placebo for 4 weeks, followed by a 4-26 week break, then switch to the other treatment for another 4 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your insulin sensitivity will be measured before and after each 4-week intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.